Foster City, California, April 18, 2007 – Entelos, Inc. (LSE: ENTL), a leading life sciences company building predictive computer models of human physiology and “virtual patients” for drug discovery and development, announced today that it has exercised its option and acquired an exclusive worldwide license to develop a series of selective progesterone-receptor modulators (SPRMs) pursuant to an agreement with Ortho-McNeil Pharmaceuticals, Inc., an affiliate of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Entelos believes that these compounds, which had previously been studied in a Phase I clinical trial by the licensor, may be useful for the treatment of a range of women’s health-related indications.
